In this section, we provide a more in-depth analysis of the four cancer-drug combinations on which most research has been done: Proteasome inhibitors for multiple myeloma, EGFR inhibitors for breast cancer, cisplatin for lung and ovarian cancer, and BRAF inhibitors for melanoma. Here, BRAF is linked to ovarian cancer.